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VP6a b s t r a c t
Enteric viruses cause diverse infectionswith substantialmorbidity andmortality in children, rotavirus (RV)
and norovirus (NoV) being the leading agents of severe pediatric gastroenteritis. Coxsackie B viruses (CVB)
are common enteroviruses (EV), associated with increased incidence of severe neonatal CVB disease with
potentially fatal consequences. To prevent majority of childhood gastroenteritis, we have developed a
non-live NoV–RV combination vaccine consisting of NoV virus-like particles (VLPs) and RV oligomeric
rVP6 protein that induced protective immune responses to NoV and RV in mice. Moreover, rVP6 acted as
an adjuvant forNoVVLPs.Here,we investigated apossibility to include a third enteric virus-derived antigen
in the candidate NoV–RV vaccine, by adding recombinant nanoparticles derived fromEV CVB1. To examine
immunogenicity of EV-NoV-RV vaccine, BALB/c mice were immunized intramuscularly twice with 10 mg
CVB1 VLPs, GII.4 VLPs and rVP6 nanotubes, either separately or combined. To evaluate the adjuvant effect
of rVP6onEV responses,mice received0.3 mgCVB1VLPswithorwithout 10 mg rVP6. Comparable serum IgG
antibodies were detected whether the antigens were administered separately or in combination. Each for-
mulation generated IgG1 and IgG2a antibodies, indicating a mixed Th2/Th1-type response. CVB1 VLPs
skewed the isotype distribution slightly towards IgG1 subtype, while EV-NoV-RV combination vaccine
induced unbiased Th1/Th2 responses to CVB1. Each antigen also induced T cell mediated immunity mea-
sured by IFN-c secretion to specific stimulants ex vivo. Antisera raised by single antigens and combined for-
mulation also exhibited strong neutralizing ability against CVB1 and NoV GII.4. Further, rVP6 showed an
adjuvant effect on CVB1 responses, sparing the VLP dose and homogenizing the responses. Finally, the
results support inclusion of additional antigens in the candidate NoV-RV combination vaccine to combat
severe childhood infections and confirm adjuvant effect of rVP6 nanostructures.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Enteric pathogens are responsible for a variety of infections
with substantial morbidity and mortality rates worldwide, espe-
cially in infants and young children. Among enteric viruses, group
A rotaviruses (RVs) and norovirus (NoV) are the two most medi-
cally important viruses in pediatric gastroenteritis (GE) [1]. Enter-
oviruses (EVs), instead, are responsible for several other commonly
encountered viral infections in childhood [2].Despite the global introduction of RV vaccinations over a dec-
ade ago and thus significant reduction in RV diarrhea-related mor-
tality and incidence, RV still accounts for almost 40% of diarrheal
hospitalizations and estimated 129,000–165,000 deaths annually
in children < 5 years of age, majority of deaths taking place in
low-income settings [1,3]. NoV infections have been estimated to
cause about 12% of severe pediatric GE cases and 10,000–70,000
deaths among the same target population [1,4]. Despite approxi-
mately 30 divergent genotypes within the GI and GII genogroups
responsible for the majority of human NoV infections [5], the
GII.4 genotype has dominated since 1990s, accounting for 55–
85% of all NoV GE worldwide [6]. There is no NoV vaccine available,
but the current vaccine candidates rely mainly on virus-like parti-
cles (VLPs), the structures resembling the native virus particles,
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[7]. For RV, alternatives to live attenuated oral RV vaccines, includ-
ing subunit vaccines, are being considered for improvement of effi-
cacy in developing countries and alleviation of risks attributable to
live vaccines [8].
Like other EVs, Coxsackievirus B (CVB) serotypes CVB1-6 cause a
wide range of illnesseswith clinicalmanifestations varying from the
mild respiratory symptoms to rare but severe complications, such as
aseptic meningitis and myocarditis, children under 3 years of age
being the most vulnerable to the severe outcomes [2,9]. Thus far,
the only licensed non-polio EV vaccines exist for EV71, but the
increasing prevalence and fatality of CVB1 infections in newborns
[9–11] aswell as a possible contribution of CVBs to the development
of type 1 diabetes [12] underscore the necessity for development of
CVB vaccines. Traditional polio vaccines and recently licensed EV71
vaccines are based on live attenuated or formalin-inactivated
viruses. However, to overcome the disadvantages related to the
whole-virus vaccines, including reversion of the vaccine virus
toward virulence, non-infectious VLPs of various EV serotypes (i.e.
CVB3, EV71, CAV6, CAV16, CAV10), formed by VP0, VP1, and VP3
capsid proteins as a result of cleavage of the polyprotein P1 by viral
protease, have been developed as safer vaccine candidates [13,14].
For protection against childhoodGE, our laboratory has proposed
a concept of vaccination against NoV and RVwith a non-live subunit
combination vaccine consisting of NoV GII.4 and GI.3 VLPs and RV
oligomeric rVP6 protein [15,16]. RV inner capsid protein VP6 is con-
sidered a potential vaccine candidate due to its extremely immuno-
genic and polymorphic nature, being able to spontaneously
assemble in vitro into diverse nanostructures, including nanotubes
[17,18]. We have previously demonstrated that parenteral and
mucosal administration of the candidate NoV–RV combination vac-
cine elicited long-lastingandbroadly reactiveheterologous immune
responses to both NoV and RV in mice [15,16,19,20] and conferred
protection against murine RV challenge [20,21]. Further, VP6 nan-
otubes andnanospheres have shownan adjuvant effect on immuno-
genicity of co-delivered NoV VLPs [22,23]. Since the number of
distinct vaccines for pediatric use is constantly increasing, combina-
tion vaccines provide an effective way to combat various childhood
infections with one shot. Accordingly, the present study explored
the possibility of combining three different recombinant virus-
derived nanoparticles, CVB1 VLPs, GII.4 VLPs and rVP6 nanotubes,
into combination vaccine against EV, NoV and RV. The results
demonstrate that no immunological interference exists between
the three tested vaccine antigens.Table 1
Antigenic formulations and immunization of experimental mice.
Experimental
group
Immunogen Injection
dose (mg)
# mice/group
I CVB1 VLP 0.3 52. Materials and methods
2.1. Production of antigens
EV CVB1 VLPs [24], NoV GII.4 VLPs and RV rVP6 proteins were
produced in baculovirus (BV)-insect cell expression systems, as
described in detail elsewhere [15,25,26]. CVB1 VLPs were purified
according to a recently developed protocol consisting of Tangential
Flow Filtration and multistep chromatographic procedures [24], a
modification of the method originally developed for CVB3 VLPs
[13]. GII.4 VLPs were purified with polyethylene glycol precipita-
tion followed by anion exchange chromatography [26,27]. RV
rVP6 was purified by sucrose gradients and ultracentrifugation
[15,25] followed by three consecutive ultrafiltration procedures
[18].II CVB1 VLP 10 5
III GII.4 VLP 10 3
IV VP6 10 3
V CVB1 VLP + GII.4 VLP + VP6 10 + 10 + 10 5
VI CVB1 VLP + VP6 0.3 + 10 5
VII PBS (Control) – 52.2. Characterization of vaccine antigens
The purity, identity and morphology of all three vaccine anti-
gens were determined using previously described procedures[18,22]. Shortly, the absence of BV was verified by a BacPAK Rapid-
Titer Kit (Takara, Cat. 631406) and SDS-PAGE followed by
immunoblotting with anti-BV gp64 antibody (Santa Cruz Biotech-
nology, Inc., Cat. sc-65499). Endotoxin levels were determined
using ToxinSensorTM Gel Clot Endotoxin Assay kit (GenScript, Cat.
L00351) according to manufacturer’s instructions.
The integrity and morphology of the protein assemblies were
examined by transmission electron microscope (TEM) with Jeol
JEM-1400 (Jeol Ltd., Tokyo, Japan) following negative staining with
3% uranyl acetate (pH 4.6). Hydrodynamic diameter (size), volume
distribution (%) and polydispersity index (PdI) of the antigens were
determined by dynamic light-scattering (DLS) using a Zetasizer
Nano ZS (Malvern Instruments Ltd, Worcestershire, UK) equipped
with a He–Ne laser (633 nm).
2.3. Animal immunization and sample collection
Female 6-week-old BALB/c OlaHsd mice (Envigo, Horst, the
Netherlands) were randomly divided into seven groups (Gr I-VII),
acclimatized under controlled specific pathogen-free conditions
for one week prior to the start of the experiment, and maintained
throughout the study period with food and water provided ab libi-
tum. Animals were immunized twice (at study weeks 0 and 3)
intramuscularly at the right caudal thigh muscle with 50 ml of
CVB1 VLPs, GII.4 VLPs, rVP6 protein, a mixture of these three anti-
gens or a mixture of CVB1 VLPs and rVP6 (Table 1). To assess
immunogenicity induced with EV, NoV, and RV antigen alone or
in the mixture, the dose of each immunogen was 10 mg per immu-
nization point. To evaluate the adjuvant effect of VP6 on CVB1
induced response, two groups of mice received suboptimal 0.3 mg
dose of CVB1 VLPs alone or in a combination with 10 mg VP6. No
external adjuvants were included in any vaccine formulation. Con-
trol group received carrier only (sterile phosphate buffered saline,
PBS). Immunizations were conducted under general anesthesia by
inhalation of isoflurane (Attane vet, Vet Medic Animal Health Oy
Cat. AP/DRUGS/220/96).
Blood samples were taken before each immunization (study
weeks 0 and 3) by tail bleeding to test for the kinetics of the serum
antibody responses. Whole blood, feces, nasal washes (NWs) and
splenocytes were collected at the time of sacrifice (study week 5)
and processed according to the previously published procedures
[15,19,28]. Each experimental procedure was carried out in
accordance with the regulations and guidelines of the Finnish
National Experiment Board (Permission number ESAVI/
10800/04.10.07/2016). All efforts were made to minimize animal
suffering and to reduce the number of animals used. Animal health
was monitored throughout the experiment.
2.4. Antigen–specific serum and mucosal antibody responses
Serum samples of individual mice were tested in ELISA for the
presence of EV CVB1-, NoV GII.4- and RV VP6-specific IgG and
IgG subtype antibodies as described elsewhere [15,28]. Further,
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antibodies. Shortly, 96-well half-area polystyrene plates (Corning
Inc., Cat. 3690) were coated with 50 ng of CVB1 VLPs, GII.4 VLPs
or rVP6 per well. Antigen-specific antibodies in sera or mucosal
secretions were detected with horseradish peroxidase (HRP)
-conjugated anti-mouse IgG (Sigma-Aldrich, Cat. A4416), IgG1
(Invitrogen, Cat. A10551) or IgG2a (Invitrogen, Cat. A10685) and
SIGMA FAST OPD substrate (Sigma-Aldrich, Cat. P9187). Optical
densities at 490 nm (OD490) were measured by Victor2 microplate
reader (PerkinElmer, Waltham, MA). Endpoint titers were
expressed as the reciprocal of the highest sample dilution with
an OD490 above the cut-off value (>0.1 OD490 unit).
2.5. Neutralizing anti-CVB1 antibody detection
Neutralizing ability of immune sera against CVB1 (strain CVB1-
V200, kindly provided by Vactech Ltd.) was measured in fourfold
serially diluted sera by standard virus plaque reduction assay in
green monkey kidney (GMK) cells as previously described [12]. A
reduction in plaque number  80% compared with mock-treated
virus control was considered positive. A titer of 16 was assigned
for positivity threshold of neutralizing capacity.
2.6. NoV blocking assay
The ability of serum antibodies to block NoV VLP binding to a
cellular histo-blood group antigen (HBGA) receptors was tested
with NoV blocking assay, utilizing pig gastric mucin (PGM) typeTable 2
Specifications of vaccine antigens.
Specification CVB1 VLPs GII.4 VLPs rVP6
Identity VP0, VP1 and VP3 VP1 doublet VP6
Morphology VLPs (~30 nm) VLPs (~37 nm) Tubes (~0.2–1.5 mm)
Size (d.nm)* 30.36 ± 0.20 36.60 ± 0.45 672.86 ± 57.62
Infectious BV (pfu/ml) 0 0 0
BV gp64 Negative Negative Negative
Endotoxin
(EU/10 mg protein)
<0.06 <0.02 <0.01
* Average of three measurements (each measurement containing 10–20  10 s
datasets at 25 C) ± standard deviation.
Fig. 1. Characterization of the vaccine antigens. (A) SDS-PAGE analysis of purified EV C
illustrates molecular weight marker. (B) Electron micrographs of morphological struc
nanostructures (panel 3), and a mixture (1:1:1) of aforementioned antigens (EV-NoV-RV
Black bar indicates 100 nm. (C) Dynamic light scattering (DLS) analysis of the vaccine an
(panel 1), NoV GII.4 VLPs (panel 2), RV rVP6 nanotubes (panel 3), and a mixture (1:1:1) of
results are presented as the average of three measurements (each measurement containIII (Sigma Chemicals, Cat. M1778) as a source of HBGAs [29]
according to the recently described procedure [23]. In brief, mix-
tures of pre-incubated GII.4 VLPs and serially diluted sera were
added on PGM coated 96-microwell plates and the bound VLPs
were detected with human GII.4 antiserum followed by the corre-
sponding HRP-conjugated secondary IgG (Novex, Cat. A18811). The
blocking titer 50 (BT50) was determined as the reciprocal of the
final serum dilution blocking 50% of the maximum VLP binding
determined with VLPs without serum.
2.7. Cell-mediated immune response detection
T cell responses were quantified using an ELISPOT IFN-c assay
previously published by our laboratory [16,25]. For detection of
CVB1-, GII.4-, and VP6-specific IFN-c producing cells, liquid nitro-
gen frozen splenocytes (0.2  106 cells/well) were stimulated in
duplicates with CVB1 or GII.4 VLPs (20 mg/ml) or an 18-mer VP6-
derived R6-2 peptide (5 mg/ml) previously identified as a VP6-
specific CD4+ T cell epitope (242DGATTWYFNPVILRPNNV259) [30],
respectively. Background control (culture medium) and cell viabil-
ity control (T cell mitogen Concanavalin A) were tested in each
assay. The spots representing individual IFN-c secreting cells were
counted by ImmunoSpot automatic CTL analyzer (CTL-Europe
GmbH, Bonn, Germany). The results were expressed as mean
spot-forming cells (SFC)/106 splenocytes of duplicate wells.
2.8. Statistical analyses
The statistical differences between the non-parametric observa-
tions of two or more independent groups were determined with
the Mann-Whitney U test and Kruskal-Wallis tests. Data was ana-
lyzed with GraphPad Prism software, version 8.0.1, and p < 0.05
was defined to indicate statistically significant difference.3. Results
3.1. Characterization of vaccine antigens
Purity, integrity and morphology of CVB1 VLPs, GII.4 VLPs and
rVP6 protein were verified as shown in Table 2. SDS–PAGE analysis
showed presence of EV CVB1 capsid proteins VP0, VP1 and VP3VB1 VLPs (lane 1), NoV GII.4 VLPs (lane 2), and RV rVP6 protein (lane 3). Lane M
tures assembled by EV CVB1 VLPs (panel 1), NoV GII.4 VLPs (panel 2), RV rVP6
combination vaccine, panel 4) corresponding to SDS-PAGE lanes 1–3, respectively.
tigens. Size distributions in nanometers (nm) by volume percent of EV CVB1 VLPs
aforementioned antigens (EV-NoV-RV combination vaccine, panel 4) are shown. The
ing 10–20  10 s datasets at 25 C).
Fig. 2. Antigen-specific serum IgG antibody responses following immunization
with 10 mg doses of EV CVB1 VLPs, GII.4 VLPs, or RV rVP6 or a mixture of the three
antigens. Shown are CVB1- (A), GII.4- (B), and VP6-specific (C) end-point titers of
IgG antibodies in termination sera at week 5. Each symbol represents an individual
mouse. Control (Ctrl) mice received PBS only. The solid line indicates the geometric
mean titer of the group. A titer of 100 was assigned for sera with no detectable
antibodies, being a half of the initial dilution. Horizontal dashed line indicates the
cut-off level (2 Log10).
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(Fig. 1A). No residual impurities were detected in any of the puri-
fied proteins, as antigens were free of live BV as well as BV gp64
protein (Table 2). Further, none of the antigenic formulations con-
tained bacterial endotoxins in excess levels [31] (Table 2). Each
antigen preparation consisted of particles of the expected size
and morphology, including CVB1 VLPs, GII.4 VLPs and rVP6 nan-
otubes, confirmed under TEM (Fig. 1B, Table 2). Mixing the CVB1
VLPs, GII.4 VLPs and rVP6 in equal quantities did not impair single
protein integrity or morphology (Fig. 1B).
Analysis of antigenic formulations by DLS showed that 100% of
the CVB1 VLP, GII.4 VLP and rVP6 nanotubes had respective aver-
age hydrodynamic diameters of 30 nm (PdI 0.05), 37 nm (PdI
0.10), and 673 nm (PdI 0.25) (Fig. 1C), corresponding to sizes deter-
mined by TEM (Table 2). Only two distinct populations were
observed in the combined vaccine formulation (PdI 0.78), where
CVB1 and GII.4 VLPs with close particle sizes were recognized as
the one single particle population (79%) and rVP6 nanotubes as
the distinct population (21%) (Fig. 1C).
3.2. No mutual inhibition of vaccine antigens
3.2.1. Induction of robust IgG response
To examine immunogenicity induced with EV-NoV-RV combi-
nation vaccine and possible mutual interference of the vaccine
components with immunogenicity, vaccine antigens were admin-
istered either separately or in combination at 10 mg doses/antigen.
Each vaccine antigen elicited a robust IgG response (geometric
mean titers, GMTs  4.4 Log10) (Fig. 2). No statistically significant
differences between the magnitudes of IgG antibody levels
(p  0.09) were detected whether CVB1 VLPs (Fig. 2A), GII.4 VLPs
(Fig. 2B) or rVP6 (Fig. 2C) were administered alone or in the triva-
lent combination. Sera from control mice did not show reactivity
with any of the antigens (Fig. 2).
3.2.2. Induction of mixed Th2/Th1 responses
Determination of antigen-specific IgG subtype IgG1 and IgG2a
titers, representing Th2- and Th1-type responses, revealed induc-
tion of IgG1 (GMTs  4 Log10) and IgG2a (GMTs  3.4 Log10) anti-
bodies with each antigenic formulation (Fig. 3). CVB1 VLPs alone
generated significantly higher (p = 0.018) levels of IgG1 (GMT 5.5
Log10) compared with the levels induced by the combination
(GMT 4.6 Log10) (Fig. 3A). By contrast, combined formulation
caused threefold greater anti-CVB1 IgG2a titers (GMT 4.7 Log10)
than single antigen (GMT 4.2 Log10); however, the difference was
not significant (p = 0.331) (Fig. 3B). Thus, CVB1 VLPs skewed the
response slightly towards Th2-type, while the administration in
combination with GII.4 VLPs and rVP6 resulted in better-balanced
Th2/Th1 response. Comparable GII.4-specific IgG1 (p = 0.237) and
IgG2a (p = 0.877) levels were elicited, whether GII.4 VLPs were
administered separately or in the combination with other antigens
(Fig. 3C and D). Similarly, no significant difference was observed in
the magnitude of VP6-specific IgG1 (p = 0.127) or IgG2a (p = 0.365)
responses between rVP6 alone and combined formulation (Fig. 3E
and F). No antigen-specific IgG subtype antibodies were detected
in sera of control mice (Fig. 3).
3.2.3. Induction of CVB1- and GII.4-specific neutralizing antibodies
Ability of induced antibodies to neutralize the virus was studied
as a protective potential of antisera. Fig. 4A depicts ability of serum
antibodies to neutralize CVB1. Immunization with CVB1 VLPs alone
conferred similar neutralization (GMT 446) to the combination vac-
cine (GMT 588) (p = 0.738). Sera from control mice did not exhibit
neutralization activity at 1:16, the lowest dilution tested (Fig. 4A).
Neutralizing ability of GII.4-specific antibodies was examined
measuring the blocking of GII.4 VLPs binding to the HBGAs. BothGII.4 VLP formulations induced antibodies able to block efficiently
the VLP binding (Fig. 4B). Blocking activity was comparable
(p = 0.696) whether GII.4 VLPs were administered separately
(BT50 400 ± 200) or in the trivalent combination (BT50 240 ± 40).
Control mice did not induce blocking antibodies (Fig. 4B).
3.2.4. Induction of antigen-specific IFN-c secreting T cells
Induction of T cell responses by antigenic formulations was fur-
ther characterized measuring Th1-type cytokine IFN-c production
from the splenocytes of immunized and control mice. Each vaccine
antigen elicited a considerable T cell response to ex vivo stimula-
Fig. 3. Antigen-specific serum IgG subtype antibody responses following immunization with 10 mg doses of EV CVB1 VLPs, GII.4 VLPs, or RV rVP6 or a mixture of the three
antigens. Shown are CVB1- (A, B), GII.4- (C, D), and VP6-specific (E, F) end-point titers of IgG1 (A, C, E) and IgG2a (B, D, F) antibodies in termination sera at week 5. Each symbol
represents an individual mouse. Control (Ctrl) mice received PBS only. The solid line indicates the geometric mean titer of the group. A titer of 100 was assigned for sera with
no detectable antibodies, being a half of the initial dilution. Horizontal dashed line indicates the cut-off level (2 Log10).
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quantities of IFN-c secreting cells (p  0.4) were detected whether
CVB1 VLPs (Fig. 5A), GII.4 VLPs (Fig. 5B) or rVP6 (Fig. 5C) were
administered alone or in the trivalent combination. No antigen-
specific IFN-c responses were developed by the cells of negative
control mice (Fig. 5A–C). Culture media alone stimulated no IFN-
c production by the cells from any of the groups (Fig. 5A–C).
3.3. VP6 effect on immunogenicity of CVB1 VLPs
3.3.1. Development of CVB1-specific serum antibodies
An adjuvant effect of rVP6 on CVB1-specific antibody responses
was investigated immunizing mice twice with 0.3 mg of CVB1 VLPsalone or together with 10 mg of rVP6. Moreover, results of mice
immunized with 10 mg dose of CVB1 VLPs were included for com-
parison. Fig. 6A depicts development of serum anti-CVB1 IgG anti-
bodies at weeks 0, 3 and 5. Three weeks after the first dose, IgG was
present in all experimental groups. However, the first 0.3 mg dose
of CVB1 VLPs alone induced only minor IgG response (OD490
0.243 ± 0.139), antibody levels being significantly lower
(p = 0.039) than the levels induced by 10 mg of CVB1 VLPs (OD490
1.108 ± 0.275) and co-administration of 0.3 mg with rVP6 (OD490
0.752 ± 0.152) (Fig. 6A). Instead, co-delivery of CVB1 VLPs with
rVP6 evoked equally high (p = 0.347) IgG response with 10 mg dose
of VLPs alone. No significant differences in the responses were
observed after the second dose administration, given at week 3,
Fig. 4. Neutralizing antibodies induced by 10 mg of EV CVB1 or GII.4 VLPs, or a trivalent EV-NoV-RV combination consisting of CVB1 VLPs, GII.4 VLPs and rVP6 nanostructures.
Control (Ctrl) mice received PBS only. (A) Neutralizing antibody titers against CVB1. Each symbol represents an individual mouse. The solid line indicates the geometric mean
titer of the group. A titer of 8 was assigned for all serum samples with no detectable neutralizing antibodies, being a half of the initial dilution. Horizontal dashed line
indicates the positivity threshold of neutralizing capacity (1.2 Log10). (B) Homologous blocking of GII.4 VLP binding to histo-blood group antigens. The results are expressed as
the mean blocking indexes (%) of experimental groups (±SEM), calculated as follows: 100% - OD490 ((wells with serum) / OD490 (wells without serum)  100%). The horizontal
dashed line represents the blocking titer 50% (BT50).
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remained negative for antigen-specific IgG response during the
whole study period (Fig. 6A).
CVB1-specific serum IgG, IgG1 and IgG2a antibody titers of
immunized mice are shown in Fig. 6B–D. Regardless of lack of sig-
nificance in the magnitudes of IgG (p = 0.196) (Fig. 6B) or IgG1
(p = 0.289) (Fig. 6C), mice receiving 0.3 mg dose of CVB1 VLPs in
combination with rVP6 developed tenfold greater and more uni-
form responses than the mice receiving 0.3 mg dose of CVB1 VLPs
alone. Similarly, addition of rVP6 in the CVB1 VLP formulation
increased IgG2a titers fourfold, although the difference was statis-
tically insignificant (p = 0.398) (Fig. 6D).
3.3.2. Development of serum neutralizing antibodies
Irrespective of CVB1 VLP formulation, all experimental groups
mounted a considerable neutralization activity of CVB1 (Fig. 6E).
No statistical difference in anti-CVB1 neutralizing titers
(p = 0.915) was observed between the mice receiving 0.3 mg of
CVB1 VLPs alone (GMT 256) or combined with 10 mg of rVP6
(GMT 339), but the neutralizing titers were somewhat more evenly
distributed after inclusion of rVP6. These neutralizing antibody
responses were comparable (p = 0.169) with the response induced
by 10 mg dose of CVB1 (GMT 446).
3.3.3. Increase in anti-CVB1 cellular immunity
Irrespective of CVB1 VLP formulation, splenocytes from immu-
nized mice responded with considerable IFN-c release, when stim-
ulated with CVB1 VLPs (Fig. 6F). Regardless of a lack of significance
in the magnitudes of IFN-c responses (p = 0.057), mice receiving
0.3 mg dose of CVB1 VLPs in combination with rVP6 developed two-
fold greater quantities of IFN-c secreting cells than the mice receiv-
ing 0.3 mg dose of CVB1 VLPs alone. The T cell responses were
comparable (p = 0.4) with the response induced by 10 mg dose of
CVB1.
3.3.4. Induction of anti-CVB1 antibodies in mucosal secretions
To investigate if rVP6 has an influence on stimulation of anti-
bodies at mucosal surfaces, group-wise pooled 10% fecal suspen-
sions and individual NW specimens were tested for the presence
of anti-CVB1 IgG. Comparison of fecal responses (Fig. 7A) indicated
that 0.3 mg dose of CVB1 VLPs induced twofold lower levels of
intestinal IgG (endpoint titer 10) than 10 mg dose or 0.3 mg doseco-administered with rVP6 (endpoint titers 20). As expected, anti-
bodies in nasal secretions (Fig. 7B) showed similar pattern to that
observed in feces. Of mice immunized with 0.3 mg dose of VLPs in
the absence of rVP6, only 1/5 had low level of nasal IgG (GMT
3.3). In comparison, nasal lavages showed fourfold increase in
mucosal IgG levels (p = 0.109), when mice received either 10 mg
dose (GMT 15.2) or 0.3 mg dose co-administered with rVP6 (GMT
13.2), but the levels varied among individual mice. Control mice
had no detectable mucosal anti-CVB1 IgG antibodies (Fig. 7).4. Discussion
Combination vaccines are the cornerstones for public health
benefits, reducing the number of required injections while increas-
ing immunization compliance. Incorporation of diphtheria, pertus-
sis and tetanus antigens into a single vaccine formulation
represents the first successful example of combination vaccines
[32]. Due to the high global social and economic burden caused
by RV and NoV infections [1], our laboratory has recently devel-
oped a combined non-live subunit vaccine against these two fre-
quent causes of childhood GE [15,16]. The candidate vaccine
consisting of NoV GII.4 and GI.3 VLPs and RV rVP6 protein was
highly immunogenic in mice by inducing protective immune
responses against NoV and RV [15,16,21]. To combat many com-
mon enteric childhood infections with the same vaccine, this study
was aimed to investigate possibility to include EV antigens in the
candidate NoV–RV combination vaccine. Based on the increased
incidence of severe CVB disease with potentially fatal cardiological
and neurological involvement [9–11], we selected CVB1 as a model
pathogen and generated EV-NoV-RV combination vaccine compris-
ing EV CVB1 VLPs, NoV GII.4 VLPs and RV rVP6 nanotubes. To
exclude a potential immunological interference of distinct anti-
genic components [32], we compared antigen-specific immuno-
genicity raised by individual antigens and EV-NoV-RV
combination vaccine. While comprehensive preclinical studies
with the NoV–RV vaccine have already demonstrated no mutual
interference and/or inhibition of NoV GII.4 VLPs, NoV GI.3 VLPs,
and RV rVP6 with antibody and T cell responses [15,16], the pre-
sent study indicates unaltered GII.4- and VP6-specific systemic
antibody and T cell responses by CVB1 VLPs. Thus, this data sup-
ports the possibility to add EV (CVB) antigens to NoV–RV candidate
vaccine.
Fig. 5. Antigen-specific T cell responses following immunization with 10 mg doses
of EV CVB1 VLPs, GII.4 VLPs, or RV rVP6 or a mixture of the three antigens. Shown
are CVB1- (A), GII.4- (B), and VP6-specific (C) IFN-c responses following stimulation
of splenocytes with CVB1 or GII.4 VLPs or VP6-specific R6-2 peptide. Control (Ctrl)
mice received PBS only. Results are expressed as mean IFN-c spot forming cells
(SFC)/106 cells of experimental groups with standard error of the means. The
dashed lines indicate the cut-off limit obtained from cells incubated in a culture
media (CM) only (mean SFC/106 + 3  SD).
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responses by CVB1 VLPs, GII.4 VLPs and rVP6 nanotubes demon-
strated high immunogenicity of all antigens. Serum IgG levels were
comparable whether the antigens were administered separately or
in the trivalent combination, suggesting immunological compati-
bility of the three antigens. Further, analysis of IgG subclasses as
markers of cellular responses revealed that each antigenic formu-
lation generated IgG1 and IgG2a responses, indicating a mixed
antigen-specific Th2/Th1-type response. Induction of cellular
immunity by each antigenic formulation was confirmed measuringantigen-specific IFN-c cytokine production, a hallmark of Th1 cell
immunity. The multivalent antigen expression, size and morphol-
ogy of CVB1 VLPs, GII.4 VLPs and rVP6 nanotubes make these anti-
gens potent inducers of antibodies and T cell responses, through
efficient cross-linking of B cell receptors [33] and internalization
by antigen-presenting cells (APCs) [34]. Observed responses are
consistent with induction of both Th1 and Th2 cells previously
seen with delivery of NoV VLPs, RV rVP6 as well as NoV–RV com-
bination vaccine [15,16]. Administration of CVB1 VLPs alone
skewed the isotype distribution towards IgG1 subtype, whereas
combination vaccine promoted unbiased Th1/Th2 responses to
CVB1. In concordance with the immunity induced by CVB1 VLP for-
mulations, EV71 VLPs have also been reported to stimulate a mixed
Th1- and Th2-type response in IM immunized mice [35].
Although the role of cell-mediated immune responses in the EV
clearance and protection is less characterized, CD4+ and CD8+ T cell
responses, in addition to neutralizing antibodies, have been
demonstrated to be involved in immunity induced by oral polio-
virus vaccine [36]. Similarly, T cell immunity appears to have a role
in the generation of heterologous NoV immunity [37,38]. In con-
trast to EV and NoV VLPs derived from viral capsid protein/s, RV
inner capsid VP6 protein does not elicit classical neutralizing anti-
bodies, but pIgR-mediated intracellular neutralization and CD4+ T
cells are considered the principal mediators of VP6-inducecd pro-
tection [39,40]. Indeed, we have recently demonstrated an ability
of rVP6 nanostructures to induce Th1, Th2 and Th17 cell subsets
as well as CD4+ cytotoxic T lymphocytes with the potential to lyse
RV infected cells [41].
To explore functionality of induced immunity, protective poten-
tial of antibodies in terms of neutralization was confirmed. Antis-
era raised by CVB1 VLPs, either separately or in trivalent
combination, exhibited a strong neutralizing capacity against the
homologous CVB1 strain in vitro. This is in agreement with the
robust IgG1 responses, which have been associated with EV neu-
tralization [42]. Neutralization titers were comparable with those
induced previously with inactivated CVB1 vaccine [43] as well as
CVB3 VLPs [13]. In support of good compatibility of CVB1, GII.4
and rVP6 antigens, Wang and colleagues [44] have observed no
interference between EV71 and GII.4 VLPs with respect to their
protective potential.
Despite the recent progress in cultivation of NoV in vitro, the
blocking assay is still employed as a surrogate measure for NoV
neutralization. NoV-specific antibodies, which block the binding
of NoV VLP to its putative HBGA receptors or attachment factors,
are considered the best correlate of protection against NoV infec-
tion [45–47]. The data in this study demonstrated that inclusion
of CVB1 VLPs in the candidate NoV–RV vaccine formulation did
not alter the blocking potential of anti-GII.4 antibodies.
We have previously reported rVP6 oligomers to have adjuvant
properties, promoting adaptive immune responses against co-
delivered NoV VLPs [23]. rVP6 was shown to improve responses
to the foreign antigenic peptides, when employed as an immuno-
logical carrier [48]. Thus, this study was extended to investigate
adjuvant effect of rVP6 on immunogenicity of CVB1 VLPs, employ-
ing the suboptimal 0.3 mg dose of CVB1 VLPs according to our pre-
vious studies with NoV VLPs [22,23]. In here, the suboptimal dose
of CVB1 VLPs induced unexpectedly high if variable responses,
hampering to address an evident adjuvant action of rVP6. How-
ever, the addition of rVP6 did result in constantly more uniform
CVB1-specific responses, referring to the stabilizing effect of rVP6
in the formulation. Although rVP6 nanostructures were shown to
improve the blocking potential of NoV-specific antibodies
[22,23], the similar effect of rVP6 could not be observed on protec-
tive CVB1-specific responses, possible due to the considerable
immunogenicity of CVB1 VLPs at the selected dose. However, the
more consistent neutralization titers mirrored the more consistent
Fig. 6. Development of EV CVB1-specific antibodies and T cell responses following immunization with 0.3 mg or 10 mg of CVB1 VLPs alone or 0.3 mg dose formulated with 10 mg
of rVP6. Control (Ctrl) mice received PBS only. (A) Kinetics of total IgG antibodies in sera. Group mean OD490 values with standard error of means of 1:200 diluted sera at
indicated study weeks are shown. Immunizations at study weeks 0 and 3 are shown with arrows. Horizontal dashed line indicates the cut-off level (OD490  0.1). End-point
titers of IgG (B), IgG1 (C), and IgG2a (D) antibodies in termination sera at week 5. Each symbol represents an individual mouse. The solid line indicates the geometric mean
titer of the group. A titer of 100 was assigned for sera with no detectable antibodies, being a half of the initial dilution. Horizontal dashed line indicates the cut-off level (2
Log10). (E) Protective potential of anti-CVB1 antibodies. Shown are neutralizing antibody titers against CVB1, each symbol representing an individual mouse. The solid line
indicates the geometric mean titer of the group. A titer of 8 was assigned for all serum samples with no detectable neutralizing antibodies, being a half of the initial dilution.
Horizontal dashed line indicates the positivity threshold of neutralizing capacity (1.2 Log10). (F) IFN-c production by T cells. Splenocytes from immunized mice were
simulated ex vivowith CVB1 VLPs. Results are expressed as mean IFN-c spot forming cells (SFC)/106 cells of experimental groups with standard error of the means. The dashed
line indicates the cut-off limit obtained from cells incubated in a culture media (CM) only (mean SFC/106 + 3  SD).
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the experimental design with a lower dose of CVB1 VLPs needs to
be accomplished. Nevertheless, the adjuvant effect of VP6 on NoV-
specific immune responses has been elucidated to be dependent on
co-delivery and co-localization of the antigens [22,23]. Accord-
ingly, RV VP6 upregulates expression of antigen presentation
molecules, co-stimulatory molecules, and pro-inflammatory
cytokines on APCs [49], creating a favorable environment for
uptake and presentation of co-delivered antigens.
In conclusion, our data shows that neither NoV GII.4 VLPs nor
RV rVP6 nanotubes interfered with EV CVB1-specific antibodylevels or vice versa. Therefore, it may be possible to include CVB1
VLPs, and possibly other EV antigens, in the NoV–RV candidate vac-
cine formulation in order to generate vaccine against divergent
enteric infections. The current study supports our previous obser-
vation that rVP6 nanostructures have desirable features attributed
to classical adjuvants [22,23], which function to spare the dose of
the antigens and accelerate and improve the immune responses.
Thus, rVP6 nanotubes do not only act as an adjuvant for NoV VLPs
but they also exert an adjuvant effect on CVB1-specific responses.
Overall, these findings further support the use of RV VP6 protein in
combined vaccines against enteric pathogens.
Fig. 7. Mucosal CVB1-specific antibody responses following immunization with 0.3 mg or 10 mg of CVB1 VLPs alone or 0.3 mg dose formulated with 10 mg of rVP6. End-point
titrations of anti-CVB1 IgG antibodies in 10% fecal suspensions (A) or nasal washes (NWs) (B) of experimental mice. Control (Ctrl) mice received PBS only. Mean titration
curves with standard errors of the mean of the experimental groups are shown. Horizontal dashed line indicates the cut-off level (OD490  0.1).
S. Heinimäki et al. / Vaccine 37 (2019) 7509–7518 7517Declaration of Competing Interest
The authors declare the following financial interests/personal
relationships which may be considered as potential competing
interests: H.H. is a minor (5%) shareholder and member of the board
of Vactech Ltd, which develops vaccines against picornaviruses. H.
H. serves on the scientific advisory board of Provention Bio Inc.,
which is developing an enterovirus vaccine. The other authors have
no conflict of interest to declare.Acknowledgements
We gratefully acknowledge the Electron Microscopy Unit of the
Institute of Biotechnology, University of Helsinki. Special thanks
are due to Dr. Helena Vihinen and Mervi Lindman for the guidance
and technical help in transmission electron microscopy. The tech-
nical assistance given by the personnel of Vaccine Research Center
and Ulla Kiiskinen from Protein Dynamics group of Tampere
University is acknowledged. We also express our gratitude to
members of the animal facility at Tampere University. We
acknowledge Business Finland (project THERDIAB 1843/31/2014)
for financial support and the partners of the THERDIAB project
(ArcDia Ltd., Vactech Ltd., JILab Ltd., FimLab Ltd.) for their support.
Finally, we acknowledge Biocenter Finland for infrastructure
support.Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.vaccine.2019.09.072.References
[1] GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional,
and national morbidity, mortality, and aetiologies of diarrhoea in 195
countries: a systematic analysis for the Global Burden of Disease Study
2016. Lancet Infect Dis 2018;18(11):1211–1228.
[2] Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. Enterovirus
surveillance–United States, 1970–2005. MMWR Surveill Summ 2006;55
(8):1–20.
[3] Clark A, Black R, Tate J, Roose A, Kotloff K, Lam D, et al. Estimating global,
regional and national rotavirus deaths in children aged. PLoS One 2017;12(9):
e0183392.
[4] Mattison CP, Cardemil CV, Hall AJ. Progress on norovirus vaccine research:
public health considerations and future directions. Expert Rev Vacc 2018;17
(9):773–84.[5] Parra GI, Squires RB, Karangwa CK, Johnson JA, Lepore CJ, Sosnovtsev SV, et al.
Static and evolving norovirus genotypes: implications for epidemiology and
immunity. PLoS Pathog 2017;13(1):e1006136.
[6] Ramani S, Atmar RL, Estes MK. Epidemiology of human noroviruses and
updates on vaccine development. Curr Opin Gastroenterol 2014;30(1):25–33.
[7] Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and
antigenicity of the Norwalk virus capsid protein. J Virol 1992;66(11):6527–32.
[8] Afchangi A, Jalilvand S, Mohajel N, Marashi SM, Shoja Z. Rotavirus VP6 as a
potential vaccine candidate. Rev Med Virol 2019;29(2):e2027.
[9] Wikswo ME, Khetsuriani N, Fowlkes AL, Zheng X, Peñaranda S, Verma N, et al.
Increased activity of Coxsackievirus B1 strains associated with severe disease
among young infants in the United States, 2007–2008. Clin Infect Dis 2009;49
(5):e44–51.
[10] Baek K, Yeo S, Lee B, Park K, Song J, Yu J, et al. Epidemics of enterovirus
infection in Chungnam Korea, 2008 and 2009. Virol J 2011;8:297.
[11] Verma NA, Zheng XT, Harris MU, Cadichon SB, Melin-Aldana H, Khetsuriani N,
et al. Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates.
Clin Infect Dis 2009;49(5):759–63.
[12] Sioofy-Khojine A, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala
H, et al. Coxsackievirus B1 infections are associated with the initiation of
insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia
2018;61(5):1193–202.
[13] Koho T, Koivunen MRL, Oikarinen S, Kummola L, Mäkinen S, Mähönen AJ, et al.
Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong
immune responses in mice. Antiviral Res 2014;104:93–101.
[14] Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, et al. A virus-like particle-
based tetravalent vaccine for hand, foot, and mouth disease elicits broad and
balanced protective immunity. Emerg Microbes Infect 2018;7(1):94.
[15] Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and
rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Vaccine 2011;29(45):8126–33.
[16] Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent
combination vaccine induces broad heterologous immune responses to
norovirus and rotavirus in mice. PLoS ONE 2013;8(7):e70409.
[17] Lepault J, Petitpas I, Erk I, Navaza J, Bigot D, Dona M, et al. Structural
polymorphism of the major capsid protein of rotavirus. EMBO J 2001;20
(7):1498–507.
[18] Lappalainen S, Vesikari T, Blazevic V. Simple and efficient ultrafiltration
method for purification of rotavirus VP6 oligomeric proteins. Arch Virol
2016;161(11):3219–23.
[19] Tamminen K, Malm M, Vesikari T, Blazevic V. Mucosal antibodies induced by
intranasal but not intramuscular immunization block norovirus GII.4 virus-
like particle receptor binding. Viral Immunol 2016;29(5):315–9.
[20] Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-
Guadarrama F, Palomares LA, et al. Immune responses elicited against
rotavirus middle layer protein VP6 inhibit viral replication in vitro and
in vivo. Hum Vaccin Immunother 2014;10(7):2039–47.
[21] Lappalainen S, Pastor A, Malm M, López-Guerrero V, Esquivel-Guadarrama F,
Palomares L, et al. Protection against live rotavirus challenge in mice induced
by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch
Virol 2015;160(8):2075–8.
[22] Blazevic V, MalmM, Arinobu D, Lappalainen S, Vesikari T. Rotavirus capsid VP6
protein acts as an adjuvant in vivo for norovirus virus-like particles in a
combination vaccine. Hum Vaccin Immunother 2016;12(3):740–8.
[23] Malm M, Heinimäki S, Vesikari T, Blazevic V. Rotavirus capsid VP6 tubular and
spherical nanostructures act as local adjuvants when co-delivered with
norovirus VLPs. Clin Exp Immunol 2017;189(3):331–41.
[24] Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine A-B,
Marjomäki V, et al. Formalin treatment increases the stability and
7518 S. Heinimäki et al. / Vaccine 37 (2019) 7509–7518immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Research
2019;171. https://doi.org/10.1016/j.antiviral.2019.104595.
[25] Lappalainen S, Tamminen K, Vesikari T, Blazevic V. Comparative
immunogenicity in mice of rotavirus VP6 tubular structures and virus-like
particles. Hum Vaccin Immunother 2013;9(9):1991–2001.
[26] Koho T, Huhti L, Blazevic V, Nurminen K, Butcher SJ, Laurinmäki P, et al.
Production and characterization of virus-like particles and the P domain
protein of GII.4 norovirus. J Virol Methods 2012;179(1):1–7.
[27] Koho T, Mäntylä T, Laurinmäki P, Huhti L, Butcher SJ, Vesikari T, et al.
Purification of norovirus-like particles (VLPs) by ion exchange
chromatography. J Virol Methods 2012;181(1):6–11.
[28] Tamminen K, Huhti L, Koho T, Lappalainen S, Hytönen VP, Vesikari T, et al. A
comparison of immunogenicity of norovirus GII-4 virus-like particles and P-
particles. Immunology 2012;135(1):89–99.
[29] Lindesmith LC, Debbink K, Swanstrom J, Vinje J, Costantini V, Baric RS, et al.
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol
2012;86(2):873–83.
[30] McNeal MM, Basu M, Bean JA, Clements JD, Choi AH-, Ward RL. Identification
of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus
following intranasal immunization of BALB/c mice. Virology 2007;363
(2):410–8.
[31] Brito LA, Singh M. Acceptable levels of endotoxin in vaccine formulations
during preclinical research. J Pharm Sci 2011;100(1):34–7.
[32] Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob
Infect Dis 2011;3(1):63–72.
[33] Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM.
The influence of antigen organization on B cell responsiveness. Science
1993;262(5138):1448–51.
[34] Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-
dependent immunogenicity: therapeutic and protective properties of nano-
vaccines against tumors. J Immunol 2004;173(5):3148–54.
[35] Cao L, Mao F, Pang Z, Yi Y, Qiu F, Tian R, et al. Protective effect of enterovirus–
71 (EV71) virus–like particle vaccine against lethal EV71 infection in a
neonatal mouse model. Mol Med Rep 2015;12(2):2473–80.
[36] Wahid R, Cannon MJ, Chow M. Virus-specific CD4+ and CD8+ cytotoxic T-cell
responses and long-term T-cell memory in individuals vaccinated against
polio. J Virol 2005;79(10):5988–95.
[37] Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, et al.
Heterotypic humoral and cellular immune responses following Norwalk virus
infection. J Virol 2010;84(4):1800–15.[38] MalmM, Tamminen K, Vesikari T, Blazevic V. Norovirus-specific memory T cell
responses in adult human donors. Front Microbiol 2016;7:1570.
[39] Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, et al. Human
rotavirus VP6-specific antibodies mediate intracellular neutralization by binding
to a quaternary structure in the transcriptional pore. PLoSONE2013;8(5):e61101.
[40] McNeal MM, VanCott JL, Choi AH, Basu M, Flint JA, Stone SC, et al. CD4 T cells
are the only lymphocytes needed to protect mice against rotavirus shedding
after intranasal immunization with a chimeric VP6 protein and the adjuvant
LT(R192G). J Virol 2002;76(2):560–8.
[41] Heinimäki S, Malm M, Vesikari T, Blazevic V. Intradermal and intranasal
immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2
and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential.
Antiviral Res 2018;157:1–8.
[42] Cao R, Dong D, Liu R, Han J, Wang G, Zhao H, et al. Human IgG subclasses
against enterovirus Type 71: neutralization versus antibody dependent
enhancement of infection. PLoS ONE 2013;8(5):e64024.
[43] Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Määttä JAE,
Larsson PG, et al. Optimized production and purification of Coxsackievirus B1
vaccine and its preclinical evaluation in a mouse model. Vaccine 2017;35
(30):3718–25.
[44] Wang X, Ku Z, Dai W, Chen T, Ye X, Zhang C, et al. A bivalent virus-like particle
based vaccine induces a balanced antibody response against both enterovirus
71 and norovirus in mice. Vaccine 2015;33(43):5779–85.
[45] Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk
virus-like particles to ABH histo-blood group antigens is blocked by antisera
from infected human volunteers or experimentally vaccinated mice. J Virol
2002;76(23):12335–43.
[46] Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, et al.
Serological correlate of protection against norovirus-induced gastroenteritis. J
Infect Dis 2010;202(8):1212–8.
[47] Malm M, Uusi-Kerttula H, Vesikari T, Blazevic V. High serum levels of
norovirus genotype-specific blocking antibodies correlate with protection
from infection in children. J Infect Dis 2014;210(11):1755–62.
[48] Redmond MJ, Ohmann HB, Hughes HP, Sabara M, Frenchick PJ, Poku SK, et al.
Rotavirus particles function as immunological carriers for the delivery of
peptides from infectious agents and endogenous proteins. Mol Immunol
1991;28(3):269–78.
[49] Malm M, Tamminen K, Lappalainen S, Vesikari T, Blazevic V. Rotavirus
recombinant VP6 nanotubes act as an immunomodulator and delivery vehicle
for norovirus virus-like particles. J Immunol Res 2016;2016:9171632.
